Clinical Effectiveness
Compared with high-flux membranes, the MCO membrane increased the elimination of large middle molecules, resulting in decreased predialysis solute concentrations of solutes ranging between 11.8 and 45 kDa. Although dialysis membrane did not normalize serum concentrations of these solutes, the net effect of enhanced clearance within the large middle-molecule spectrum could explain the range of beneficial clinical effects reported to date.1
Importance of Clinical Effectiveness
Uremic toxins exhibit a wide range of physiochemical properties leading to diverse molecular and cellular level effects that contribute to morbidity and mortality among patients with end-stage renal disease.1
Large-middle molecules comprised a diverse group of biomarkers including cytokines, adipokines, hormones, and other proteins that are implicated in chronic inflammation, cardiovascular disease, and secondary immunodeficiency.2
Primary clinical studies illuminate the benefits of HDx therapy enabled by Theranova dialyzer
Ciceri P, Tettamanti G, Galassi A, et al. Pro-calcifying analysis of uraemic serum from patients treated with medium cut-off membrane in a prospective, cross-over study.
The MCO membrane might decrease uraemic serum pro-calcifying and necrotic effects through albumin loss without any clinical signs of hypoalbuminaemia.3
Willy K, Girndt M, Voelkl J, et al. Expanded Haemodialysis Therapy of Chronic Haemodialysis Patients Prevents Calcification and Apoptosis of Vascular Smooth Muscle Cells in vitro
Expanded hemodialysis therapy reduced in vitro markers of calcification, which could mean a reduction in vascular calcification and corresponding cardiovascular mortality in patients with chronic kidney disease.4
Korucu B, Yeter H, Gonen S, Kursat Derici M, Ronco C, Derici U. Impact of medium cut-off membranes on S100A12 and soluble receptor for advanced glycation end products.
This study suggests that prolonged use of MCO membrane dialyzer is associated with better S100A12-sRAGE profiles than low-flux and high-flux dialyzers.5
Kim YG, Lee SH, Jung SW, et al. The Medium Cut-Off Membrane Does Not Lower Protein-Bound Uremic Toxins
Clearance of the protein-bound uremic toxins (PBUTs) indoxyl sulfate (IS) and p-cresyl sulfate (pCS) was not different across the three different dialysis methods (HF-HD, post-OL-HDF, MCO-HD).6
Reference library
Hear from patients, nephrologists, and nurses alike share their experience prescribing HDx therapy. Be reassured by the pioneering commitment of Baxter to dialysis patients the world over and learn how Theranova dialyzers are made.
HDx Therapy Evidence Compendium
On-going research and clinical reporting are an integral part of the HDx therapy journey. Explore the the expanding evidence related to HDx therapy enabled by Theranova dialyzer that nephrologists around the world continue to generate.
HDx Therapy Brochure
Here you can find the HDx therapy brochure with more information about prescribing HDx therapy for your hemodialysis patients.
HDx Therapy Specification Sheets
Here you can find the detailed profiles of Theranova dialyzers.
Important Safety Information
Theranova dialyzers are indicated for treatment of chronic and acute renal failure by hemodialysis.
*Do not use Theranova dialyzers in HDF or HF mode.
For safe and proper use of this device, please refer to Instructions for Use.
